Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

ock-based compensation expense
  • Net loss of $8 million to $10 million
  • Basic and diluted net loss of $0.20 to $0.25 per share
  • Year-end cash, cash equivalents and investments available for sale balance greater than $30 million
  • Revenues:"We expect development revenues in 2013 will be comprised of approximately $19 million in committed R&D funding and license fee revenues from existing collaborations, and we anticipate $6 million to $9 million in additional license fees, R&D funding, milestones and cost reimbursements," Rogers noted. 

    "We forecast the vast majority of 2013 commercial revenues to be based on existing collaboration agreements.  While it remains difficult to forecast commercial revenues due to uncertainties around product launch timing, the number of product lines that will include our flavor ingredients, and other factors, we are currently estimating 2013 commercial revenues to be approximately $6 million.

    "2013 should prove to be a transitional year for Senomyx as we implement our direct sales strategy," Rogers stated.  "While direct sales are not expected to yield significant results in 2013, our goal is for direct sales to be a key driver of meaningful commercial revenues in future years.

    Expenditures:"Looking at expenditures, as we consider our resource requirements over the next several years for R&D, G&A and Commercial Operations, excluding the cost of commercial revenues, we expect we will be able to manage our expenses to be generally in-line with our 2013 expense guidance range, subject to quarterly fluctuations and increases for inflation.
    With respect to the expanded commercial organization activities in support of our direct sales strategy, many of the functions will be handled by existing Senomyx personnel.  In other cases, such as supply chain and account management, we will add dedicated resources to support these functions.
    '/>"/>

    SOURCE Senomyx
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    7. WuXi PharmaTech Announces Third-Quarter 2011 Results
    8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    9. Spherix Announces Third Quarter Financial Results
    10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... October 29, 2014 Global polyvinyl chloride ... world economic crisis during 2008-2009, especially in North America ... and currently is keeping to a growing trend. , ... is utilized in the construction segment. In 2013, the ... profiles, tubing, sheets and rigid film. Moreover, the PVC ...
    (Date:10/30/2014)... 30, 2014 James Sherley says he has ... tissue stem cell technology since his days as a principal ... in the late 1990’s. Sherley founded the ASCTC as ... holds all the intellectual property developed in Sherley’s research over ... Massachusetts Institute of Technology (MIT), and more recently as a ...
    (Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
    (Date:10/27/2014)... Cary, North Carolina (PRWEB) October 27, 2014 ... was invited earlier this month to sit down with Bryan ... Spencer from RPG Solutions to discuss talent in the Research ... the topics that were highlighted at the roundtable ... in the Triangle, the significance of work/life balance and the ...
    Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3
    ... MINNEAPOLIS, Dec. 7, 2011 Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat voiding ... and Medi Jiwani, Vice President and CFO, will present ... Oppenheimer 22nd Annual Healthcare Conference at 2:10 PM ET ...
    ... IN - Researchers from Purdue and Harvard universities have ... material that could replace silicon and have a 3-D ... approach could enable engineers to build faster, more compact ... less heat than today,s. The transistors contain tiny nanowires ...
    ... Monsanto , a major biotech corporation ... been given the  Worst Company of 2011 Award ... The award was given by  natural health information ... the worst company of 2011. Numerous ...
    Cached Biology Technology:Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference 2New '3-D' transistors promising future chips, lighter laptops 2New '3-D' transistors promising future chips, lighter laptops 3Monsanto Declared Worst Company of 2011 by NaturalSociety 2
    (Date:10/29/2014)... released by unconventional oil and gas production are well ... in the open access journal Environmental Health . ... found. The study is the first to be based ... sites and could be used to supplement official air-quality ... reserves that do not readily flow to the surface. ...
    (Date:10/29/2014)... and environmental, have been blamed for increasing the ... as a family history of schizophrenia, are widely ... gondii , a parasite transmitted by soil, undercooked ... skepticism. , A new study by Gary Smith, ... University of Pennsylvania,s School of Veterinary Medicine, used ...
    (Date:10/29/2014)... – As bodies decompose, their types and numbers ... they provide could mean the difference between a ... State University is using a more than $866,000 ... death-scene investigators examine these changing populations. The microbial ... location of death, gender, race, socioeconomic relations and ...
    Breaking Biology News(10 mins):Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3MSU partners with Detroit to investigate death scenes 2
    ... To gain insights into group dynamics for the study of ... role to play. Enter "Robofish", a computer-controlled replica stickleback that ... of biologists from the University of Leeds in the UK, ... on what motivates fish in a shoal to change direction ...
    ... of years as an herbal remedy to prevent or treat ... herbal medicines in North America. However, in spite of its ... body,s immune system are conflicting. Now researchers ... are investigating the possibility that Echinacea has other potentially more ...
    ... The U.S. Food & Drug Administration (FDA) has granted Investigational ... clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, ... University of the Negev. This is the first time ... AAT is an FDA-approved off-patent drug currently used to treat ...
    Cached Biology News:Fish with chips 2FDA approves trial for type 1 diabetes treatment by Ben-Gurion U. and U. Colorado 2
    ... D kit is an enzymeimmunoassay intended ... D (25-OH D) and other hydroxylated ... Our patented DIRECT assay technology eliminates ... centrifugation and therefore facilitates automation on ...
    Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
    7G10 anti-Fasciclin III...
    Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
    Biology Products: